Drug Review: Fosfomycin—A Rarely used but more Practical Approach for Urinary Tract Infections
Sangeeta Yadav, Omkar Singh
Citation Information :
Yadav S, Singh O. Drug Review: Fosfomycin—A Rarely used but more Practical Approach for Urinary Tract Infections. J South Asian Feder Obs Gynae 2015; 7 (2):68-70.
The mechanism of action of fosfomycin (phosphonomycin). Ann NY Acad Sci 1974 May 10;235(0):364-386.
St. Louis: Forest Laboratories, Inc.; 1997.
Fosfomycin: an old, new friend. Eur J Clin Microbiol Infect Dis 2010 Feb;29(2):127-142.
Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. Infection 1990;18(Suppl 2):S65-69.
Formation of an adduct between fosfomycin and glutathione: a new mechanism of antibiotic resistance in bacteria. Antimicrob Agents Chemother 1988 Oct;32(10):1552-1556.
Plasmid-mediated resistance to fosfomycin in staphylococcus epidermidis. FEMS Microbiol Lett 1989 Oct;52(1-2):133-137.
Fosfomycin. Available at: http://hopkins-abxguide.org/antibiotics/antibacterial/misc/fosfomycin Accessed 2/10/11.
Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010 Sep;65(9):1862-1877.
Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther 1999 Nov;21(11):1864-1872.
Single-dose fosfomycin trometamol versus multiple-dose cotrimoxazole in the treatment of lower urinary tract infections in general practice. Multicenter Group of General Practitioners. Chemotherapy 1990;36(Suppl 1):37-40.
Comparison efficacy of single dose fosfomycin with ciprofloxacin in the treatment of urinary tract infection in symptomatic women. Turk Uroloji Dergisi 2008;34(3):360-362.
Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2010 Sep;54(9):4006-4008.
Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extendedspectrum beta-lactamases. Antimicrob Agents Chemother 2009 Mar;53(3):1278-1280.
In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 1999 Feb;43(2):211-217.
In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis 2002 Apr;42(4):269-271.
Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin. Scand J Infect Dis 2003;35(1): 12-14.
